Determination of Ilaprazole and Domperidone in Individual Dosage form Tablets by RP-HPLC

Ilaprazole (Fig. 1) is a new proton-pump inhibitor not previously studied in human patients with ulcer disease. This study evaluated and compared it with a reference proton-pump inhibitor omeprazole in the treatment of gastric and duodenal ulcers. Proton-pump inhibitors have been used therapeutically for many years and show great efficacy in accelerating ulcer healing. Currently researches are focused on more potent protonpump inhibitors. Some preclinical studies have shown that ilaprazole might be such a new substitute. The chemical structures of enantiomers is ilaprazole [-[(4-methoxy-3-methyl-pyridin2-yl) methylsulfinyl]-6-pyrrol-1-yl-1H. Benzoimidazole and a substituted benzimidazole, is a new candidate drug that is an H/K-ATP ase inhibitor designed for the treatment of gastric ulcers. Ilaprazole was under development by IIYang Pharmacy Co. (Seoul, Korea) and has been proven by a series of animal studies to be a potent and safety antiulcer agent and the major one being ilaprazole sulfone. Recently, a new metabolite of ilaprazole, ilaprazole thiol ether, was identified an improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma. A validated method was performed in accordance with current guidelines, 212 gastric ulcer patients (median age 53.3 years) and 306 duodenal ulcer patients (median age 49.7 years) were recruited. Determination of Ilaprazole and Domperidone in Individual Dosage form Tablets by RP-HPLC